Top-Rated StocksTop-RatedNASDAQ:TSHA Taysha Gene Therapies (TSHA) Stock Price, News & Analysis $2.30 +0.03 (+1.32%) (As of 07/26/2024 ET) Add Compare Share Share Today's Range$2.21▼$2.3550-Day Range$2.04▼$4.1752-Week Range$0.62▼$4.32Volume1.09 million shsAverage Volume2.62 million shsMarket Capitalization$430.15 millionP/E RatioN/ADividend YieldN/APrice Target$6.60 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends Get Taysha Gene Therapies alerts: Email Address Taysha Gene Therapies MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside187.0% Upside$6.60 Price TargetShort InterestBearish11.13% of Shares Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.53Based on 6 Articles This WeekInsider TradingAcquiring Shares$3 M Bought Last QuarterProj. Earnings GrowthGrowingFrom ($0.41) to ($0.39) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.3.44 out of 5 starsMedical Sector318th out of 936 stocksBiological Products, Except Diagnostic Industry46th out of 154 stocks 4.5 Analyst's Opinion Consensus RatingTaysha Gene Therapies has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 10 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageTaysha Gene Therapies has been the subject of 7 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about Taysha Gene Therapies' stock forecast and price target. Previous Next 1.0 Short Interest Percentage of Shares Shorted11.13% of the outstanding shares of Taysha Gene Therapies have been sold short.Short Interest Ratio / Days to CoverTaysha Gene Therapies has a short interest ratio ("days to cover") of 7.9.Change versus previous monthShort interest in Taysha Gene Therapies has recently increased by 54.72%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldTaysha Gene Therapies does not currently pay a dividend.Dividend GrowthTaysha Gene Therapies does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for TSHA. Previous Next 3.1 News and Social Media Coverage News SentimentTaysha Gene Therapies has a news sentiment score of 0.53. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.News Coverage This WeekMarketBeat has tracked 6 news articles for Taysha Gene Therapies this week, compared to 3 articles on an average week.Search Interest16 people have searched for TSHA on MarketBeat in the last 30 days. This is an increase of 60% compared to the previous 30 days.MarketBeat Follows15 people have added Taysha Gene Therapies to their MarketBeat watchlist in the last 30 days. This is an increase of 150% compared to the previous 30 days. Previous Next 3.3 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Taysha Gene Therapies insiders have bought more of their company's stock than they have sold. Specifically, they have bought $2,999,999.00 in company stock and sold $0.00 in company stock.Percentage Held by InsidersOnly 2.70% of the stock of Taysha Gene Therapies is held by insiders.Percentage Held by Institutions77.70% of the stock of Taysha Gene Therapies is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Taysha Gene Therapies' insider trading history. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Taysha Gene Therapies are expected to grow in the coming year, from ($0.41) to ($0.39) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Taysha Gene Therapies is -4.69, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Taysha Gene Therapies is -4.69, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioTaysha Gene Therapies has a P/B Ratio of 5.75. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about Taysha Gene Therapies' valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad DTIWe’re in a code red crisis and 99% of Americans are clueless Folks, it's 2024… Things that we used to rely on - are failing us. Take the phasing out of fossil fuels… Matched with the destruction of oil refineries around the world… And the outright failure of solar and wind technologies… But there is just one solution… And right now governments around the world are stockpiling this resource at the fastest rate in DECADES! And how YOU can prepare for the next 2024 BOOM here! About Taysha Gene Therapies Stock (NASDAQ:TSHA)Taysha Gene Therapies, Inc., a gene therapy company, focuses on developing and commercializing adeno-associated virus-based gene therapies for the treatment of monogenic diseases of the central nervous system. It primarily develops TSHA-120 for the treatment of giant axonal neuropathy; TSHA-102 for the treatment of Rett syndrome; TSHA-121 for the treatment of CLN7 disease; TSHA-118 for the treatment of CLN1 disease; TSHA-105 for the treatment of for SLC13A5 deficiency; TSHA-113 for the treatment of tauopathies; TSHA-106 for the treatment of angelman syndrome; TSHA-114 for the treatment of fragile X syndrome; and TSHA-101 for the treatment of GM2 gangliosidosis. Taysha Gene Therapies, Inc. has a strategic partnership with The University of Texas Southwestern Medical Center. Taysha Gene Therapies, Inc. was incorporated in 2019 and is headquartered in Dallas, Texas.Read More TSHA Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart TSHA Stock News HeadlinesJuly 2, 2024 | insidertrades.comTaysha Gene Therapies, Inc. (NASDAQ:TSHA) Major Shareholder Acquires $2,999,999.25 in StockJuly 26 at 4:52 PM | markets.businessinsider.comBuy Rating Affirmed: Taysha Gene Therapies’ TSHA-102 Shows Promising Efficacy and Quality of Life Improvements in Rett SyndromeJuly 26, 2024 | WealthPress (Ad)This TSLA short trade is on a nine win hot streakMost Tesla Shareholders are disappointed in the stock's performance in 2024. Year to date, it's down 30%... And things don’t seem to be getting better. That said, one professional trader has found a way to turn Tesla’s demise into a flurry of opportunity… In fact, he has not lost a single trade on Tesla this year. As of this mailing he’s 9 for 9 with incredible wins under his belt. Just see for yourself.July 24 at 11:53 AM | americanbankingnews.comTaysha Gene Therapies (NASDAQ:TSHA) Receives Buy Rating from Needham & Company LLCJuly 17, 2024 | americanbankingnews.comFY2024 EPS Estimates for Taysha Gene Therapies, Inc. Lifted by Analyst (NASDAQ:TSHA)July 5, 2024 | globenewswire.comTaysha Gene Therapies Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)June 26, 2024 | globenewswire.comTaysha Gene Therapies Announces Pricing of Public Offering of Common Stock and Pre-Funded WarrantsJune 26, 2024 | investorplace.comWhy Is Taysha Gene Therapies (TSHA) Stock Down 14% Today?July 26, 2024 | WealthPress (Ad)This TSLA short trade is on a nine win hot streakMost Tesla Shareholders are disappointed in the stock's performance in 2024. Year to date, it's down 30%... And things don’t seem to be getting better. That said, one professional trader has found a way to turn Tesla’s demise into a flurry of opportunity… In fact, he has not lost a single trade on Tesla this year. As of this mailing he’s 9 for 9 with incredible wins under his belt. Just see for yourself.June 26, 2024 | benzinga.comWorthington Enterprises Posts Downbeat Results, Joins Taysha Gene Therapies, General Mills And Other Big Stocks Moving Lower In Wednesday's Pre-Market SessionJune 25, 2024 | globenewswire.comTaysha Gene Therapies Announces Proposed Public Offering of Common Stock and Pre-Funded WarrantsJune 19, 2024 | seekingalpha.comTaysha Gene Therapies: Latest Rett Data Checks Momentum, Road Ahead RockyJune 18, 2024 | benzinga.comWhat's Going On With Taysha Gene Therapies Stock Tuesday?June 18, 2024 | globenewswire.comTaysha Gene Therapies Announces Positive Clinical Data Across Adult and Pediatric Patients from Low Dose Cohort in Ongoing REVEAL Phase 1/2 Trials Evaluating TSHA-102 in Rett SyndromeJune 13, 2024 | investorplace.comHow to Invest in Penny Stocks in 2024: 3 Best PicksJune 12, 2024 | globenewswire.comTaysha Gene Therapies to Present Clinical Data from Both REVEAL Phase 1/2 Trials During Company-Hosted Webcast and at 2024 IRSF Rett Syndrome Scientific MeetingJune 7, 2024 | globenewswire.comTaysha Gene Therapies Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)June 3, 2024 | insidermonkey.comIs Taysha Gene Therapies, Inc. (NASDAQ:TSHA) the Best Gene Therapy Company?See More Headlines Receive TSHA Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Taysha Gene Therapies and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings5/14/2024Today7/26/2024Next Earnings (Estimated)8/12/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Biological products, except diagnostic Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:TSHA CUSIPN/A CIK1806310 Webwww.tayshagtx.com Phone214-612-0000FaxN/AEmployees180Year Founded2020Price Target and Rating Average Stock Price Target$6.60 High Stock Price Target$8.00 Low Stock Price Target$5.00 Potential Upside/Downside+187.0%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage10 Analysts Profitability EPS (Most Recent Fiscal Year)($0.49) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-111,570,000.00 Net Margins-833.60% Pretax Margin-833.60% Return on Equity-782.81% Return on Assets-55.24% Debt Debt-to-Equity Ratio0.75 Current Ratio3.38 Quick Ratio3.38 Sales & Book Value Annual Sales$15.45 million Price / Sales27.84 Cash FlowN/A Price / Cash FlowN/A Book Value$0.40 per share Price / Book5.75Miscellaneous Outstanding Shares187,020,000Free Float181,969,000Market Cap$430.15 million OptionableOptionable Beta0.41 Social Links 7 Stocks That Could Be Bigger Than Tesla, Nvidia, and GoogleGrowth stocks offer a lot of bang for your buck, and we've got the next upcoming superstars to strongly consider for your portfolio.Get This Free Report Key ExecutivesMr. Sean P. Nolan (Age 56)CEO & Chairman Comp: $925.33kDr. Sukumar Nagendran M.D. (Age 57)President, Head of Research & Development and Director Comp: $820.59kMr. Kamran Alam CPA (Age 46)M.B.A., CFO & Corporate Secretary Comp: $573.36kHayleigh CollinsDirector of Corporate Communications & Investor RelationsMs. Tracy M. Porter SPHRChief People OfficerMr. Frederick Porter Ph.D.Chief of Staff & Technical Operations OfficerMs. Emily McGinnis M.P.H.Chief Patient Advocacy & External Affairs OfficerMr. Sean McAuliffeChief Business OfficerDr. Steven Gray Ph.D.Chief Scientific Advisor of UT Southwestern Gene Therapy ProgramBerge Minassian M.D.Chief Medical Advisor of UT Southwestern Gene Therapy ProgramMore ExecutivesKey CompetitorsNantKwestNASDAQ:NKAthira PharmaNASDAQ:ATHAVaxartNASDAQ:VXRTTCR2 TherapeuticsNASDAQ:TCRRPassage BioNASDAQ:PASGView All CompetitorsInsiders & InstitutionsBank of New York Mellon CorpBought 454,464 shares on 7/26/2024Ownership: 0.243%Quantum Private Wealth LLCBought 32,000 shares on 7/17/2024Ownership: 0.391%Paul B ManningBought 1,333,333 shares on 6/27/2024Total: $3.00 M ($2.25/share)RA Capital Management L.P.Sold 7,600,000 shares on 5/17/2024Ownership: 5.814%Artal Group S.A.Bought 24,444 shares on 5/17/2024Ownership: 1.972%View All Insider TransactionsView All Institutional Transactions TSHA Stock Analysis - Frequently Asked Questions How have TSHA shares performed this year? Taysha Gene Therapies' stock was trading at $1.77 at the beginning of 2024. Since then, TSHA shares have increased by 29.9% and is now trading at $2.30. View the best growth stocks for 2024 here. How were Taysha Gene Therapies' earnings last quarter? Taysha Gene Therapies, Inc. (NASDAQ:TSHA) announced its quarterly earnings results on Tuesday, May, 14th. The company reported ($0.10) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.11) by $0.01. The business had revenue of $3.41 million for the quarter, compared to the consensus estimate of $3.70 million. Taysha Gene Therapies had a negative net margin of 833.60% and a negative trailing twelve-month return on equity of 782.81%. When did Taysha Gene Therapies IPO? Taysha Gene Therapies (TSHA) raised $125 million in an initial public offering on Thursday, September 24th 2020. The company issued 6,600,000 shares at a price of $18.00-$20.00 per share. Goldman Sachs, Morgan Stanley and Jefferies served as the underwriters for the IPO and Chardan was co-manager. Who are Taysha Gene Therapies' major shareholders? Top institutional investors of Taysha Gene Therapies include Quantum Private Wealth LLC (0.39%) and Bank of New York Mellon Corp (0.24%). Insiders that own company stock include RA Session II, Sean P Nolan, Paul B Manning, Suyash Prasad, Kamran Alam, Sukumar Nagendran and Phillip B Donenberg. View institutional ownership trends. How do I buy shares of Taysha Gene Therapies? Shares of TSHA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:TSHA) was last updated on 7/26/2024 by MarketBeat.com Staff From Our Partners625,000% GainImagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetche...Crypto Swap Profits | Sponsored“Generational Bull Run” IncomingLIVE Cash Flow Workshop Event / Hosted Virtually Weds @ 7PM EST Everyone who attends will also receive 3 sp...Unstoppable Prosperity | SponsoredThis student turned $1,300 into $45,000 in just 4 Months!With the help of S.A.M. (my new AI-powered scanner) it's now easier than ever to find these unique trades... ...Monument Traders Alliance | SponsoredCollapse of the PetrodollarThe death of the "petrodollar" seems imminent. And the implications could not be worse for Americans. Ru...Colonial Metals | SponsoredRare signal predicts 50% market drop - before electionThe market is near all-time highs, we're told that unemployment is low, AI's a gift to humanity, and the FED w...Behind the Markets | SponsoredMust-See: Elon’s New Invention is Absolutely InsaneCould Elon's New Device be Bigger than the iPhone? According to 30-year Silicon Valley and Wall Street vete...InvestorPlace | SponsoredElon to Transform U.S. Economy? A radical, potentially game-changing technology that threatens to destroy the trillion-dollar, “green energy” ...Porter & Company | Sponsored5 Stocks that could triple in a week Robinhood traders have piled $78 billion into this market... Driving tiny tech stock gains of 3,000%, 8,942...Traders Agency | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Taysha Gene Therapies, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Taysha Gene Therapies With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
